Company news

Vaxcyte, Inc. news in 2023

Vaxcyte, Inc.'s news releases, calls and decks from 2023, newest first.

View company

VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

December 3, 2023

Vaxcyte Appoints Jacks Lee to Board of Directors

November 27, 2023

Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates

November 26, 2023

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults

November 8, 2023

Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update

November 5, 2023

Vaxcyte to Present at Upcoming Investor Conferences

October 30, 2023

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults

October 18, 2023

Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)

October 15, 2023

Vaxcyte to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

September 18, 2023

Vaxcyte Reports Second Quarter 2023 Financial Results and Provides Business Update

August 7, 2023

Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

July 10, 2023

Vaxcyte to Present at the Jefferies Healthcare Conference

May 31, 2023

Vaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update

May 7, 2023

Vaxcyte to Present at the BofA Securities 2023 Health Care Conference

May 2, 2023

Vaxcyte Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

April 20, 2023

Vaxcyte Announces Pricing of $500 Million Public Offering

April 18, 2023

Vaxcyte Reports Positive Data from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24, in Adults Aged 65 and Older and Full Six-Month Safety Data from Adult Phase 1/2 and Phase 2 Studies

April 16, 2023

Vaxcyte to Host Webcast and Conference Call to Discuss Results from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate in Adults Aged 65 and Older and Full Six-Month Safety Data from Both Adult Phase 2 Studies

April 15, 2023

Vaxcyte Doses First Participants in Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

March 29, 2023

Vaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

February 26, 2023

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

February 20, 2023

Vaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023

February 15, 2023

Vaxcyte to Present at the SVB Securities Global Biopharma Conference

February 6, 2023

Vaxcyte’s VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults

January 4, 2023

Calls in 2023

Decks in 2023